ca 6

Anti-CA6 Antibody (huDS6) is an antibody that specifically targets the sialic acid sugar epitope associated with mucin 1 (CA6). It is utilized in the synthesis of antibody-drug conjugates (ADCs).

INCA-6 (Triptycene-1,4-quinone) is a cell-permeable NFAT inhibitor that disrupts CN-NFAT signaling by targeting the NFAT(P) substrate at the calcineurin (CN) phosphatase site.

(6E,8E)-3-hydroxy-4,9-dimethyl-10-oxo-10-[(2,3,4,5,6-pentahydroxyhexyl)oxy]deca-6,8-dienoic acid is a high-purity biochemical reagent suitable for biochemical experiments and drug synthesis research.

(2S,3R,4S,5S,6R)-2-{[(6E)-2,10-dihydroxy-2,6,10-trimethyldodeca-6,11-dien-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol is a high-purity biochemical reagent suitable for biochemical experiments and drug synthesis research.

(6E)-heptadeca-6,16-diene-1,2,4-triol is a high-purity biochemical reagent suitable for biochemical experiments and drug synthesis research.

(6E,8E)-3-hydroxy-4,9-dimethyl-10-oxo-10-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}deca-6,8-dienoic acid is a high-purity biochemical reagent suitable for biochemical experiments and drug synthesis research.

2-amino-3-{[(6E,9E)-5-hydroxy-8-methoxy-5,9,13,14-tetramethyl-2-oxo-1-oxacyclotetradeca-6,9-dien-4-yl]sulfanyl}propanoic acid is a high-purity biochemical reagent suitable for biochemical experiments and drug synthesis research.

(6E,10E)-12-(2,6-dihydroxy-4-methylphenyl)-2,6,10-trimethyl-4-oxododeca-6,10-dien-5-yl acetate is a high-purity biochemical reagent suitable for biochemical experiments and drug synthesis research.

(2S,3R,4S,5S,6R)-2-{[(6E)-3,10-dihydroxy-2,6,10-trimethyldodeca-6,11-dien-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol is a high-purity biochemical reagent suitable for biochemical experiments and drug synthesis research.

2-acetamido-3-{[(4R,5R,6E,8S,9E,13S,14R)-5-hydroxy-8-methoxy-5,9,13,14-tetramethyl-2-oxo-1-oxacyclotetradeca-6,9-dien-4-yl]sulfanyl}propanoic acid is a high-purity biochemical reagent suitable for biochemical experiments and drug synthesis research.

Linoleyl Bromide ((6Z,9Z)-18-bromooctadeca-6,9-diene) is an intermediate for synthesizing lipid nanoparticles.

AMCA-6-dUTP is suitable for the enzymatic labeling of DNA/cDNA [1].

(2S,3R,4S,5S,6R)-2-{[(6E,10E)-2,12-dihydroxy-2,6,10-trimethyldodeca-6,10-dien-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol is a high-purity biochemical reagent suitable for biochemical experiments and drug synthesis research.

Staurosporine (AM-2282) is a protein kinase inhibitor with ATP-competitive and non-selective inhibitory activity (IC50=6/15/2/3/3000 nM) against PKC, PKA, c-Fgr, phosphorylase kinase and TAOK2. Staurosporine also induces apoptosis.

PF-3450074 (PF-74) acts at an early stage of HIV-1 infection inhibits viral replication by directly competing with the binding of CPSF6 (nuclear host factors cleavage and polyadenylation specific factor 6) and NUP153 (nucleoporin 153), and blocks the uncoating, assembly, and the reverse transcription steps of the viral life cycle. PF-3450074 is a specifical inhibitor of HIV-1 capsid protein (CA) and shows a broad-spectrum inhibition of HIV isolates with submicromolar potency (EC50=8-640 nM).

Carbonic anhydrase-IN-35 is a selective inhibitor of carbonic anhydrase (CA), demonstrating potent inhibition of tumor-associated hCA IX (Ki= 0.6 nM) and hCA XII (Ki= 2.2 nM). It induces autophagic apoptosis in MCF-7 cells by increasing Bax, decreasing Bcl-2, and downregulating CDK4/6. Carbonic anhydrase-IN-35 exhibits significant cytotoxicity against MCF-7 (IC50= 0.3975 μM normoxia / 0.6575 μM hypoxia), MCF-7-ADR (IC50= 0.3975 μM normoxia / 4.488 μM hypoxia), MDA-MB-231, and 4T1 breast cancer cells. This compound is applicable in breast cancer research.

BI-9627 hydrochloride is a highly potent Na⁺/H⁺ exchanger 1 (NHE1) inhibitor. In intracellular pH recovery assays and human platelet swelling assays, its IC₅₀ values are 6 nM and 31 nM, respectively. It shows more than 30-fold selectivity over NHE2 and has no significant inhibitory effect on NHE3. BI-9627 hydrochloride can reduce the autophagy level of HTR-8/SVneo cells, significantly decrease the intracellular pH of human sperm, partially reverse the effect of DMA, and prolong the Ca²⁺ recovery time in KO hiPSC-CMs. BI-9627 hydrochloride has a low risk of drug-drug interactions, exhibits favorable pharmacokinetic properties in rats and dogs, and demonstrates potent activity in an ex vivo heart model of ischemia-reperfusion injury.

1. Crebanine iv 5mg/kg can eonvert BaCl_2-induced arrhythmia into sinus rhythm in rats, and can significantly increase the tolerant dose of aconitine to produce ventrieular fibrillation(VF) and cardiac arrest (CA) in rata. 2. Crebanine can also decrease t

O-desmethyl Brinzolamide is an active metabolite of the carbonic anhydrase (CA) inhibitor brinzolamide .1,2It inhibits CAII and CAIV (IC50s = 0.136 and 165 nM, respectively).1 1.Huang, Q., Rui, E.Y., Cobbs, M., et al.Design, synthesis, and evaluation of NO-donor containing carbonic anhydrase inhibitors to lower intraocular pressureJ. Med. Chem.58(6)2821-2833(2015) 2.Lo Faro, A.F., Tini, A., Gottardi, M., et al.Development and validation of a fast ultra-high-performance liquid chromatography tandem mass spectrometry method for determining carbonic anhydrase inhibitors and their metabolites in urine and hairDrug Test Anal.13(8)1552-1560(2021)

Cyclic ADP-Ribose (ammonium salt) (cADPR) is an endogenous NAD⁺ metabolite that triggers Ca²⁺ release from ER stores via ryanodine receptors and is synthesized by CD38 and CD157. It may also activate TRPM2 in a temperature-dependent manner. Showing potential in research related in inflammation and immunology.

Zonisamide-13C2,15N is intended for use as an internal standard for the quantification of zonisamide by GC- or LC-MS. Zonisamide (T0267) is an antiepileptic agent.1 It selectively inhibits the repeated firing of sodium channels (IC50 = 2 μg/ml) in mouse embryo spinal cord neurons and inhibits spontaneous channel firing when used at concentrations greater than 10 μg/ml.2 In rat cerebral cortex neurons, zonisamide (1-1,000 μM) inhibits T-type calcium channels with a maximum reduction of 60% of the calcium current.3 Zonisamide (T0267) inhibits H. pylori recombinant carbonic anhydrase (CA) and the human CA isoforms I, II, and V with Ki values of 218, 56, 35, and 21 nM, respectively.4,5 In mice, it has anticonvulsant activity against maximal electroshock seizure (MES) and pentylenetetrazole-induced maximal, but not minimal, seizures (ED50s = 19.6, 9.3, and >500 mg/kg, respectively). Zonisamide (T0267) (40 mg/kg, p.o.) prevents MPTP-induced decreases in the levels of dopamine , but not homovanillic acid or dihydroxyphenyl acetic acid , and increases MPTP-induced decreases in the dopamine turnover rate in mouse striatum in a model of Parkinson's disease.6 Formulations containing zonisamide have been used in the treatment of partial seizures in adults with epilepsy.

Reticuline is an anti-inflammatory and antihypertensive natural product that reduces JAK2/STAT3 and NF-κB phosphorylation levels, inhibits TNF-α and IL-6 mRNA expression, thereby alleviating oedema in rats.

hCAI/II-IN-6 is a selective and orally active inhibitor of human carbonic anhydrase (CA). hCAI/II-IN-6 inhibited hCA I, hCA II, hCA VII, and hCA XII with Ki values of 220, 4.9, 6.5, and ＞50,000 nM. hCAI/II-IN-6 showed anticonvulsant activity in vivo. hCAI/II-IN-6 can be used to study epilepsy. hCAI/II-IN-6 showed anticonvulsant activity in vivo. hCAI/II-IN-6 can be used to study epilepsy.

Efonidipine HCl (NZ-105) serves as both a T-type and L-type calcium channel blocker. This compound, distinct from other calcium channel blockers, notably increases N(6), 2'-O-dibutyryladenosine 3',5'-cyclic monophosphate (dbcAMP)-induced StAR mRNA and DHEA-S production in NCI-H295R adrenocortical carcinoma cells, actions reflective of adrenocorticotropic hormone. Efonidipine uniquely inhibits calcium channels by merging tonic and use-dependent blocking methods. Its inhibitory concentrations (IC50) for I(Ca(T)) and I(Ca(L)) are 0.35 micromol/l and 1.8 nmol/l, respectively. Clinically, efonidipine administered to hypertensive patients undergoing chronic hemodialysis (20-60 mg, twice daily) demonstrated comparable blood pressure control to amlodipine (2.5-7.5 mg, once daily) over a 12-week period without significantly altering pulse rate. Furthermore, efonidipine significantly improved left ventricular ejection fraction in heart failure models without affecting blood pressure, in addition to lowering the heart rate by about 10%.